| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squibb (NYSE: BMY), a leading biopharmaceutical company, today announced an expanded strategic collaboration aimed at accelerating the development of innovative cancer therapies and increasing access to clinical trials for patients across the U.S.
Central to the collaboration is SCRI's Accelero, a next-generation clinical trial delivery model that streamlines operations and accelerates trial execution across SCRI's expansive network of more than 200 locations. By aligning Bristol Myers Squibb's pioneering oncology pipeline with SCRI's research infrastructure and expertise, the collaboration is designed to bring cutting-edge research directly to patients—where they live and receive care.
Posted In: BMY
